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Summary There is no information on the effect of food or concurrent drug administration on the
bioavailability of oral etoposide, despite the fact that treatment is frequently administered over several days
and most often in combination with other cytotoxic agents. The influence of these factors has been studied in
11 patients, receiving combination cytotoxic therapy for extensive small cell lung carcinoma. Neither food nor
concurrent oral or intravenous chemotherapy had a significant effect on the mean plasma concentrations of
etoposide, achieved following oral administration. Wide variation in peak plasma concentrations and in area
under the concentration*time curve (AUC) occurred both between and within patients. It appears unnecessary
for patients receiving etoposide (at 100mg) to fast prior to drug administration. Furthermore, oral etoposide
(at 100mg and at 400mg) may be given in combination with other cytotoxic agents without compromising its
bioavailability.
Etoposide was introduced into clinical trials in the
early 1970s (Issell, 1982) and is established in the
treatment of several malignancies, including small
cell lung cancer, germ cell tumours and lymphomas
(Arnold, 1979; Issell & Crooke, 1979; Vogelzang et
al., 1982).
The demonstration of schedule dependency in
both experimental systems (Dombernowsky &
Nissen, 1973; Rozencweig et al., 1977; D'Incalci &
Garattini, 1982) and possibly also in man (Cavalli
et al., 1978; Pedersen & Hansen, 1983) has led to
most schedules of therapy being given over several
(usually 3-5) days (Arnold, 1979; Nissen et al.,
1980; Issell, 1982).
The bioavailability of the oral etoposide capsule
has been shown to be approximately 50% but with
large variation between patients (D'Incalci et al.,
1982; Harvey et al., 1984a). Despite the widespread
use of oral etoposide over 3-5 days and its
predominant use as part of combination chemo-
therapy regimens (Arnold, 1979; Comis, 1982;
Rivera et al., 1982; Williams & Einhorn, 1982),
there are no data concerning the influence of food
or other chemotherapy on etoposide bioavailability.
The intestinal absorption of some drugs has been
shown to be affected by both food (Melander,
1978; McLean et al., 1978; Pinkerton et al., 1980)
and chemotherapy (Pinkerton et al., 1982). The
effect of food and concomitant oral and intra-
venous chemotherapy on the bioavailability of
etoposide has therefore been studied.
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Materials and methods
Patients
Eleven patients receiving chemotherapy for
extensive small cell lung carcinoma were studied.
All were ambulant (performance score >60%
Karnofsky et al., 1948) with normal bone marrow,
hepatic and renal function. No patients had
disturbance of the gastrointestinal tract. Eight
patients receiving primary chemotherapy were
studied on 3 separate occasions to assess the effect
of food and concomitant oral chemotherapy on
etoposide bioavailability (Study 1). Six patients (3
of whom had previously been part of the above
study) were receiving therapy for relapsed extensive
SCLC and were studied on 3 successive days to
assess the effect of intravenous and oral chemo-
therapy on etoposide bioavailability (Study 2).
Treatment
Study 1. The effect offood and oral chemotherapy
on etoposide bioavailability Patients received
etoposide weekly as part of a combination chemo-
therapy regimen. Etoposide pharmacokinetics were
studied on 3 separate occasions at least one week
apart. Each patient thus acted as his own control.
Etoposide was administered as a single 100mg
capsule with sufficient water (- 50ml) to allow
swallowing. Patients were fasted overnight prior to
administration of etoposide. On one occasion
etoposide was taken alone following the fast, on
another occasion immediately after oral cyclophos-
phamide (100mgm-2) and oral methotrexate
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(12.5mgm-2) and on the third occasion etoposide
was taken as the only drug with a standard
breakfast. The order of these treatments was
randomised. Breakfast consisted of milk 100ml,
cornflakes 20 g, sugar 10 g, 1 egg, 1 sausage, 1 slice
white bread, 7g margarine, 20g orange marmalade
and 150ml coffee or tea, sweetened to taste.
Except in the one schedule, when taken
immediately before the etoposide, the cyclophos-
phamide and methotrexate were taken on day 2
after completion of the pharmacokinetic study.
Food and drink were allowed ad libitum 4h after
etoposide administration.
Study 2. The effect of oral and intravenous
chemotherapy on etoposide bioavailability Patients
received etoposide 400mg orally as capsules on 3
consecutive days as part of a combination chemo-
therapy regimen. Patients were fasted overnight and
for 4h after etoposide administration. On day 1
patients received etoposide alone, on day 2 it was
given 15min after adriamycin (35mg m-2) intra-
venously and procarbazine (60mgm-2) orally and
on day 3 it was given after a second dose of
procarbazine. Etoposide was administered with
sufficient water to allow swallowing (100-200ml).
No patient required regular antiemetic therapy and
metoclopramide was never used.
Sampling and assay
After an overnight fast an heparinised polyethylene
catheter was introduced into a suitable forearm vein
under local anaesthesia. A pretreatment sample was
taken. After etoposide administration, blood
samples were taken at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,
3, 3.5, 4, 4.5, 5, 6, 8, 10, 12 and 24h. Blood
samples were taken into lithium/heparin tubes
separated and stored at -20°C until assay. Urine
was collected following etoposide administration for
24h. The total daily quantity was measured and an
aliquot taken and stored at -20°C until assay. One
patient was unable to collect his urine reliably and
these specimens were discarded.
Assay was performed using reverse phase high
performance liquid chromatography with detection
by ultra violet absorbance at 229 nm as previously
described (Harvey et al., 1985). The lower limit of
sensitivity was <100 ngml-1 and coefficients of
variation were <4% within-run and <7%
between-run.
Calculation and statistics
Pharmacokinetic profiles were plotted using Stripe
(Johnston & Woollard, 1983) an interactive
computer program for the analysis of drug
pharmacokinetics. This program calculates AUC by
the trapezoidal method extrapolating to infinity.
Where appropriate (i.e. on successive study days)
the effect of residual concentrations from the
previous day was removed by curve stripping. AUC
values are presented corrected to a standard surface
area of 1.7m2 to compensate for the fixed dosage
to patients of varying body build. The volume of
distribution (Vd) was calculated from the formula:
Vd=- Dose
AUCx k
(where k=elimination rate constant), clearance (Cl)
from the formula:
Cl =Vdxk
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and bioavailability from the ratio AUC following
oral administration to AUC followed intravenous
administration expressed as a percentage. The
statistical significance was calculated using
Student's t-test.
Results
Study 1. The effect offood and oral chemotherapy
on etoposide bioavailability The pharmacokinetic
data are shown in Table I and the individual
patient results (AUC) are shown diagrammatically
in Figure 1. There was considerable variation
between patients both in initial values and after
food or chemotherapy. While some patients showed
alteration in AUC after food or oral chemotherapy,
there was no trend to increased or decreased values.
The apparently greater variation in etoposide bio-
Table I Pharmacokinetics of etoposide (100mg) before
and after food and concurrent oral chemotherapy
(Mean results #-95% confidence limits)
With
concurrent After
chemo- standard
Fasting therapy breakfast
Elimination half-life 6.9 7.3 7.2
(h) +1.0 +1.2 +1.1
Peak plasma conc. 5.0 4.4 3.9
(pgml) + 1.8 +2.4 +0.7
AUC 40.8 36.0 35.8
(pgml .h 1.7m2) + 10.7 + 14.0 +9.8
Urinary excretion 21 16 19
(% of dose given) +5 +10 + 4FOOD AND CHEMOTHERAPY - EFFECT ON ETOPOSIDE BIOAVAILABILITY
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Figure 1 AUC in individual patients showing the
effect of concurrent low dose oral chemotherapy and
food on etoposide bioavailability.
availability between patients after food and after
concomitant oral chemotherapy was not statistically
significant.
Study 2. The effect of oral and intravenous chemo-
therapy on etoposide bioavailability The pharmaco-
kinetic data for the 3 consecutive days are shown in
Table II and the individual patient AUCs plotted
diagrammatically in Figure 2. Despite considerable
variation within patients in both peak plasma
concentrations and AUC, neither consistent
increase or decrease was shown. The variation seen
over 3 days was no greater than that following
repeated oral administration without concurrent
Table II Pharmacokinetics of etoposide before (day 1),
together with adriamycin and procarbazine (day 2) and
together with procarbazine (day 3)
(Mean results +95% confidence limits)
Day I Day 2 Day 3
Elimination half-life 7.3 9.0 8.4
(h) +2.1 +3.5 +3.0
Peak plasma conc. 14.0 10.7 11.1
(pgml) +7.0 +5.3 +3.9
AUC 132.2 108.7 120.2
(pgml-'.h 1.7 2) +71.0 +50.6 +49.4
Urinary excretion 13 9 12
(%ofdosegiven) +10 +4 +7
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Figure 2 AUC in individual patients following oral
etoposide administration on 3 successive days showing
the effect of concurrent intravenous (day 2) and oral
(days 2 and 3) chemotherapy.
chemotherapy (Slevin et al., 1983). Thus intra-
venous adriamycin and oral procarbazine did not
significantly affect the bioavailability ofetoposide.
Discussion
The bioavailability of oral etoposide shows
considerable variation between patients (D'Incalci
et al., 1982; Harvey et al., 1984a) and, at least at
higher doses, variation within patients is also
significant (Slevin et al., 1983). There are several
studies of the bioavailability of etoposide following
single doses in the fasting state (Beveridge et al.,
1976; Lawrie et al., 1982; D'Incalci et al., 1982;
Slevin et al., 1983; Harvey et al., 1984a, 1985) but
despite its frequent use in schedules of treatment
combined with other drugs and spread over several
days (Arnold, 1979; Nissen et al., 1980; Comis,
1982; Issell, 1982), there are no previous data on
the effect of either concomitant chemotherapeutic
agents or of food on etoposide bioavailability.
The interaction of food and drugs is complex and
may lead to an increase, a decrease or no change in
the bioavailability of the drug (Melander, 1978).
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The interaction may be mediated via a variety of
mechanisms, including drug reaction with specific
food substances, delayed gastric emptying, altera-
tion in the rates of tablet/capsule dissolution and
altered first-pass metabolism either by an effect
directly on hepatic enzymes or on hepatic blood
flow (Melander, 1978; McLean et al., 1978). A
combination of these factors may produce
contrasting effects on the absorption of drugs of
similar chemical composition or even in different
preparations of the same drug (Welling & Tse,
1982). Such complex possibilities make predictions
impossible and only by direct studies on the drug
concerned can the question be resolved (Melander,
1978; Welling & Tse, 1982).
The effect of cytotoxic chemotherapy on
intestinal absorption has been infrequently studied,
despite the common use of drugs in combinations
(Zubrod, 1980) and a low therapeutic ratio, which
make any interaction potentially serious (Prescott,
1980). Methotrexate is one of the few cytotoxic
drugs studied. It has been shown to impair xylose
absorption but not its own absorption, following
both single and repeated doses (Pinkerton et al.,
1981).
The data shown here suggest that, at least at
doses of 100mg, food does not significantly
interfere with etoposide bioavailability and it is
probably unnecessary for patients to fast prior to
etoposide administration. This is ofparticular impor-
tance, because it is possible that administration in
divided doses may be more efficacious than in a
single dose as is the case in experimental systems
(Dombernowsky & Nissen, 1973; Rozencweig et al.,
1977; D'Incalci & Garattini, 1982) and possibly
man (Cavalli et al., 1978; Pedersen & Hansen,
1983).
Neither concomitant oral chemotherapy with
cyclophosphamide and methotrexate at low doses,
nor simultaneous treatment with intravenous
adriamycin together with oral procarbazine were
shown to affect etoposide bioavailability in a
consistent manner. There were considerable changes
in AUC with food and concurrent chemotherapy in
some patients, but these were no greater than the
variation within patients following repeated oral
etoposide in the absence of concomitant chemo-
therapy (Slevin et al., 1983). Thus it appears that
oral etoposide may be safely given as part of a
combination chemotherapy regimen without
compromising its bioavailability.
The marked variation in bioavailability both
between and within patients observed in this and
other studies appears to be due to factors other
than food and concomitant chemotherapy.
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